Cargando…

The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA

Soft tissue sarcomas (STS) are a heterogeneous group of malignancies predominantly affecting children and young adults. Despite improvements in multimodal therapies, 5-year survival rates are only 50% and new treatment options in STS are urgently needed. To develop a rational combination therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muenchow, Alina, Weller, Sandra, Hinterleitner, Clemens, Malenke, Elke, Bugl, Stefanie, Wirths, Stefan, Müller, Martin R., Schulze-Osthoff, Klaus, Aulitzky, Walter E., Kopp, Hans-Georg, Essmann, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445285/ https://www.ncbi.nlm.nih.gov/pubmed/32839432 http://dx.doi.org/10.1038/s41419-020-02910-2

Ejemplares similares

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax
por: Stehle, Daniel, et al.
Publicado: (2018)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
por: Lin, Kevin H., et al.
Publicado: (2016)

BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy
por: Pedro, Jose Manuel Bravo-San, et al.
Publicado: (2015)

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
por: Ko, Tun Kiat, et al.
Publicado: (2014)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2014)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2015)

Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1
por: Li, Lingxiao, et al.
Publicado: (2015)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Early Reconstitution of Antibody Secreting Cells after Allogeneic Stem Cell Transplantation
por: Hinterleitner, Martina, et al.
Publicado: (2022)

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X(L)–BAX interaction
por: Saleh, Tareq, et al.
Publicado: (2020)

Steady-state neutrophil homeostasis is a demand-driven process
por: Wirths, Stefan, et al.
Publicado: (2013)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016)

Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
por: Luedtke, Daniel A, et al.
Publicado: (2017)

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
por: Benito, Juliana M., et al.
Publicado: (2015)

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma
por: Dengler, M A, et al.
Publicado: (2014)

BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
por: Inoue, Chisato, et al.
Publicado: (2018)

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
por: Bodo, Juraj, et al.
Publicado: (2016)

The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
por: Shi, Yuanfei, et al.
Publicado: (2021)

Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma
por: Shi, Yuanfei, et al.
Publicado: (2022)

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
por: Nakajima, W, et al.
Publicado: (2014)

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment
por: Britt, Erin L., et al.
Publicado: (2019)

Structural Mechanism for Regulation of Bcl-2 protein Noxa by phosphorylation
por: Karim, Christine B., et al.
Publicado: (2015)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

Acute Myeloid Leukemia Cells Harboring MLL Fusion Genes or with the Acute Promyelocytic Leukemia Phenotype Are Sensitive to the Bcl-2-selective Inhibitor ABT-199
por: Niu, Xiaojia, et al.
Publicado: (2014)

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

NOXA-Induced Alterations in the Bax/Smac Axis Enhance Sensitivity of Ovarian Cancer Cells to Cisplatin
por: Lin, Chao, et al.
Publicado: (2012)

Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
por: Weiss, Johanna, et al.
Publicado: (2016)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma
por: Shan, Huizhuang, et al.
Publicado: (2020)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

Erratum: Structural Mechanism for Regulation of Bcl-2 protein Noxa by phosphorylation
por: Karim, Christine B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nsfjj06himitscned931og41kd